ObjectiveTo observe the effects of bumetanide and furosemide on cardiac function, serum high mobility group Box 1 (HMGB1) and soluble growth stimulation gene expressed protein 2 (sST2) levels in patients with acute left ventricular failure (ALVF). MethodsA total of 98 ALVF patients admitted to our hospital from January 2019 to January 2021 were selected and randomly divided into bumetanide group and furosemide group, with 49 cases in each group. Both groups were given routine anti-heart failure treatment, such as cardiotonic therapy, vascular dilation, etc. On this basis, furosemide group was treated with furosemide, while bumetanide group was treated with bumetanide, for a 7-day treatment course. The clinical therapeutic effects of the two groups were compared. The cardiac function, levels of serum HMGB1 and sST2 were compared between the two groups before and after the treatment. The average daily urine output and the occurrence of adverse reactions during treatment were compared between the two groups. ResultsAfter 7 days of treatment, the total effective rate in the bumetanide group (95.92%) was significantly higher than that in the furosemide group (83.67%), with a statistically significant difference (P＜0.05). Before treatment, there were no statistically significant differences in stroke volume (SV) and left ventricular ejection fraction (LVEF) between the two groups (P＞0.05). After 7 days of treatment, SV and LVEF in both groups increased significantly, SV and LVEF in bumetanide group were significantly higher than those in the furosemide group. During treatment, the average daily urine output of patients in bumetanide group was significantly greater than that in the furosemide group, with a statistically significant difference (P＜0.05). Before treatment, there were no statistically significant differences in the levels of HMGB1 and sST2 between the two groups (P＞0.05). After 7 days of treatment, the levels of HMGB1 and sST2 in both groups decreased significantly, but the differences between the two groups were not statistically significant (P＞0.05). There was no statistically significant difference in the occurrence of adverse reactions between the two groups during treatment (P＞0.05). ConclusionBoth bumetanide and furosemide can relieve cardiac load and reduce myocardial injury in patients with acute left ventricular failure. However, bumetanide has more significant diuretic effect and improvement of cardiac function, with better clinical treatment effect.

无